RAS blockade and cardioprotection 35. Liu J, Yang F, Yang XP, Jankowski M, Pagano PJ. NAD(P)H oxidase mediates angiotensin II-induced vascu- lar macrophage infiltration and medial hypertrophy. Arte- rioscler Thromb Vasc Biol 2003; 23: 776-82. 36. Schultz JEJ, Witt SA, Glascock BJ, et al. TGFβ1 mediates the hypertrophic cardiomyocyte growth induced by an- giotensin II. J Clin Invest 2002; 109: 787-96. 37. Kuwahara F, Kai H, Tokuda K, et al. Transforming growth factor-beta function blocking prevents myocardial fibro- sis and diastolic dysfunction in pressure overload rats. Circulation 2002; 106: 130-5. 38. Peters H, Border WA, Noble NA. Targeting TGFβ overex- pression in renal disease: Maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 1998; 54: 1570-80. 39. Azizi M, Guyene TT, Chatellier G, Wargon M, Menard J. Additive effects of losartan and enalapril on blood pres- sure and plasma active renin. Hypertension 1997; 29: 634-40. 40. Forclaz A, Maillard M, NussBerger J, Brunner HR, Burnier M. Angiotensin II receptor blockade: Is there truly a ben- efit of adding an ACE-inhibitor? Hypertension 2003; 41: 31-6. 48